Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Artículo
en Inglés
| IMSEAR
| ID: sea-91609
ABSTRACT
Patients with idiopathic hypereosinophilic syndrome (HES) show persistent hypereosinophilia of unknown etiology that is associated with end-organ damage. Different treatments, including the use of corticosteroids and cytotoxics, have been investigated for HES with modest success. We report a young patient with HES who developed stroke and remained refractory to conventional therapy. Therapy with imatinib mesylate, a selective tyrosine kinase inhibitor that is highly effective in treating patients with BCR-ABL-positive chronic myeloid leukemia, was tried with the patient. The result was impressive, with hematologic remission achieved rapidly. Our finding concurs with recent reports that imatinib mesylate may be a promising agent in the treatment of some cases of HES.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Proteínas Tirosina Quinasas
/
Humanos
/
Masculino
/
Síndrome Hipereosinofílico
/
Adulto
/
Inhibidores Enzimáticos
Idioma:
Inglés
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS